Gene Polymorphism of CYP2B6 and Susceptibility to Acute Myeloid Leukemia in Egypt

Abstract

Background: Acute myeloid leukemia (AML) is a diverse hematologic neoplasm that is distinguished by aberrant myeloid progenitor cell  growth. Genetic factors, including polymorphisms in drug-metabolizing enzymes, such as CYP2B6, have been implicated in AML  susceptibility and treatment outcomes. Understanding the association between CYP2B6 gene polymorphisms and AML risk can offer  insights into personalized treatment strategies and prognosis.

Objective: To ascertain the relationship between CYP2B6 gene  polymorphism (rs3745274) and vulnerability to AML in the Egyptian population. Additionally, the study aimed to explore the potential  connections between this genetic variation and clinical outcomes, as well as patients' survival.

Patients and methods: In the current  study, a polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP) technique using BseNI restriction enzyme was  used to investigate the CYP2B6 rs3745274 gene polymorphism in the peripheral blood and/or bone marrow of 105 AML patients and 111  healthy controls.

Results: Based on the study's findings, there was a notable increase in GT, GT+TT genotypes, and T alleles observed in  AML patients in contrast to the control group. The statistical analysis indicated that the differences in these polymorphic variants were  significant with Pvalues of 0.018, 0.011, and 0.015, respectively. However, these genetic variations were not associated with any specific FAB subtypes, clinical outcomes, or patients' survival.

Conclusion: CYP2B6 rs3745274 gene polymorphism may potentially assist in the  emergence of AML.